Study Feasibility and Site Selection

Role of PI in Site Success and Trial Quality

Posted on digi By digi

The Principal Investigator (PI) is more than a figurehead in clinical trials—they are the operational anchor for site success, trial integrity, and patient safety. Regulatory frameworks like ICH-GCP, FDA 21 CFR, and EMA guidelines define the PI as ultimately responsible for the conduct of the study at the site. However, the real impact of a PI is measured through trial execution: patient recruitment, protocol adherence, data accuracy, and inspection readiness.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Scoring Systems for PI Selection

Posted on digi By digi

Identifying the right Principal Investigator (PI) is a critical step in clinical trial site feasibility. An experienced, engaged, and protocol-aligned PI increases the likelihood of meeting enrollment goals, maintaining data quality, and avoiding regulatory issues. However, relying solely on subjective assessments or historical relationships introduces bias and inconsistency. To solve this, sponsors and CROs increasingly implement structured scoring systems that rank PIs based on predefined, quantifiable criteria.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Documenting PI Oversight Responsibilities

Posted on digi By digi

The Principal Investigator (PI) is ultimately responsible for the conduct of a clinical trial at the site level. Regulatory guidelines, particularly ICH-GCP E6(R2), FDA 21 CFR Part 312, and EMA GCP directives, mandate that this oversight be demonstrable—not just assumed. Inadequate documentation of PI involvement is one of the most common observations in FDA inspections and sponsor audits. To mitigate compliance risk, site staff and study teams must systematically document how PIs fulfill their responsibilities across the clinical trial lifecycle.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Assessing Past FDA Inspection Outcomes for PIs

Posted on digi By digi

Past performance is often the best predictor of future risk. In clinical trials, one of the most critical factors during site feasibility is the Principal Investigator’s (PI) history with regulatory inspections—particularly those conducted by the U.S. Food and Drug Administration (FDA). Sponsors, CROs, and quality teams are increasingly required to review and consider a PI’s inspection track record as part of the site qualification process, especially in light of ICH-GCP E6(R2) emphasis on quality risk management.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Use of KOL Databases in PI Identification

Posted on digi By digi

Identifying the right Principal Investigator (PI) is a cornerstone of site feasibility and trial success. Traditional methods—relying on existing site networks, referrals, or personal contacts—are increasingly insufficient in global clinical research. Sponsors and CROs now utilize Key Opinion Leader (KOL) databases to systematically identify investigators with expertise, influence, and track records in specific therapeutic areas. These platforms not only accelerate PI selection but also provide measurable insights into experience, research output, and community credibility.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Balancing New vs Experienced Investigators

Posted on digi By digi

Principal Investigator (PI) selection is one of the most critical aspects of clinical trial feasibility and site planning. Sponsors and CROs often face the dilemma of choosing between highly experienced investigators—who bring proven track records but may be overextended—and newer investigators, who may offer enthusiasm, available bandwidth, and access to untapped patient populations but lack extensive trial history. Balancing new and experienced PIs in a trial portfolio is both a science and an art, requiring structured evaluation, risk mitigation, and long-term planning.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Training and Qualification Checks for PIs

Posted on digi By digi

Principal Investigators (PIs) are the cornerstone of clinical trial site success. They hold ultimate responsibility for the conduct of a study at their site, ensuring compliance with protocol, Good Clinical Practice (GCP), and local regulations. Regulators such as the FDA, EMA, and DCGI emphasize that sponsors and CROs must select only qualified investigators. Qualification requires documented education, experience, and training that is up to date and verifiable. Failure to conduct adequate checks may result in inspection findings, delayed approvals, or compromised patient safety.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Challenges in Evaluating PI Across Global Sites

Posted on digi By digi

In multinational clinical trials, evaluating and selecting Principal Investigators (PIs) across global sites is a critical but complex task. While all PIs must meet ICH-GCP standards, regional variations in training, credentialing, regulatory oversight, and site infrastructure create significant challenges. Sponsors and CROs must implement structured, risk-based approaches to PI evaluation that account for cross-border differences while maintaining consistent global quality standards.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

Steps for Efficient Site Activation in Global Trials

Posted on digi By digi

Site activation is one of the most critical phases in the clinical trial lifecycle. Delays at this stage can derail recruitment projections, increase costs, and jeopardize regulatory timelines. In global trials, where multiple jurisdictions are involved, the complexity multiplies due to variations in ethics approvals, regulatory processes, and logistical readiness. Efficient site activation requires structured planning, standardized processes, and proactive risk management. This article provides a step-by-step guide to achieving streamlined site activation across global trials.
Click to read the full article.

Site Activation Planning, Study Feasibility and Site Selection

How to Shorten Site Start-Up Timelines

Posted on digi By digi

In global clinical trials, site start-up (SSU) is one of the most time-critical stages. Delays in activating sites directly affect patient recruitment, trial timelines, and overall development costs. Industry benchmarks show that SSU consumes up to 30–40% of the total clinical trial timeline, with bottlenecks often occurring in regulatory submissions, contract negotiations, and essential document collection. Accelerating site start-up without compromising quality or compliance has therefore become a top priority for sponsors and CROs.
Click to read the full article.

Site Activation Planning, Study Feasibility and Site Selection